Compounds for inhibiting LRRK2 kinase activity

US11034696B2 · kind B2 · utility

Assignee

• GlaxoSmithKline Intellectual Property Development Limited · GB

Inventors

• Feng Ren · Shanghai, CN
• Yingxia Sang · Shanghai, CN
• Weiqiang XING · Shanghai, CN
• Yang Zhan · Shanghai, CN
• Baowei Zhao · Shanghai, CN

Key dates

• Filing date: Jan 23, 2018
• Grant date: Jun 15, 2021
• Expiry date: Jan 23, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/10
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.